Table 1.
Correlation of preoperative serum C-reactive protein levels with patients’ clinico-pathological features in intra-hepatic cholangiocarcinoma
| Variable | All cases | Serum CRP mg/L | P valuea | |
|---|---|---|---|---|
| ≤1.8 | > 1.8 | |||
| Age (years) | 0.355 | |||
| ≤ 55b | 75 | 21 (28.0 %) | 54 (72.0 %) | |
| > 55 | 71 | 21 (32.3 %) | 44 (67.7 %) | |
| Gender | 0.018 | |||
| Male | 93 | 22 (23.7 %) | 71 (76.3 %) | |
| Female | 47 | 20 (42.6 %) | 27 (57.4 %) | |
| Location | 0.263 | |||
| Right lobe | 75 | 26 (34.7 %) | 49 (65.3 %) | |
| Left lobe | 46 | 13 (28.3 %) | 33 (71.7 %) | |
| Both lobes or quadrate lobe | 19 | 3 (15.8 %) | 16 (84.2 %) | |
| ALT | < 0.001 | |||
| Normal | 87 | 37 (42.5 %) | 50 (57.5 %) | |
| Elevated | 53 | 5 (9.4 %) | 48 (90.6 %) | |
| AST | 0.002 | |||
| Normal | 97 | 37 (38.1 %) | 60 (61.9 %) | |
| Elevated | 43 | 5 (11.6 %) | 38 (88.4 %) | |
| HbsAg | 0.417 | |||
| Positive | 55 | 15 (27.3 %) | 40 (72.7 %) | |
| Negative | 82 | 25 (30.5 %) | 57 (69.5 %) | |
| CEA (ng/ml) | 0.047 | |||
| ≤ 5 | 101 | 35 (34.7 %) | 66 (65.3 %) | |
| > 5 | 38 | 7 (16.7 %) | 31 (81.6 %) | |
| CA19-9 (U/ml) | 0.024 | |||
| ≤ 35 | 57 | 23 (40.4 %) | 34 (59.6 %) | |
| > 35 | 82 | 19 (23.2 %) | 63 (76.8 %) | |
| Tumor size (cm) | 0.119 | |||
| ≤ 5.5c | 71 | 25 (35.2 %) | 46 (64.8 %) | |
| > 5.5 | 69 | 17 (24.6 %) | 52 (75.4 %) | |
| Nodal metastasis | 0.158 | |||
| Yes | 29 | 6 (20.7 %) | 23 (79.3 %) | |
| No | 111 | 36 (32.4 %) | 75 (67.6 %) | |
| Tumor multiplicity | 0.830 | |||
| Single | 108 | 32 (29.6 %) | 76 (70.4 %) | |
| Multiple | 32 | 10 (31.2 %) | 22 (68.8 %) | |
| Intraepithelial ductal spread | 0.039 | |||
| Absent | 52 | 21 (40.4 %) | 31 (59.6 %) | |
| Present | 88 | 21 (23.9 %) | 67 (76.1 %) | |
| Vascular invasion | 0.940 | |||
| Absent | 86 | 26 (30.2 %) | 60 (69.8 %) | |
| Present | 54 | 16 (29.6 %) | 38 (70.4 %) | |
| Grade | 0.185 | |||
| I | 14 | 7 (50.0 %) | 7 (50.0 %) | |
| II | 77 | 23 (29.9 %) | 31 (70.1 %) | |
| III | 49 | 12 (24.5 %) | 37 (75.5 %) | |
| TNM | 0.011 | |||
| I-II | 78 | 30 (38.5 %) | 48 (61.5 %) | |
| III- IV | 62 | 12 (19.4 %) | 50 (80.6 %) | |
| Postoperative chemotherapy | 0.078 | |||
| Yes | 47 | 10 (21.3 %) | 37 (78.7 %) | |
| No | 93 | 32 (34.4 %) | 61 (65.6 %) | |
aChi-square test
bMedian age
cMedian size
CRP C-reactive protein, ALT alanine aminotransferase, AST aspartate aminotransferase, HbsAg hepatitis B surface antigen, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, TNM tumor-node-metastasis